BillionToOne, Inc.

BLLN Healthcare Diagnostics & Research

BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024.

Revenue
+47.2%
EPS
+164.3%
Free cash flow
+9.25%
Total debt
+60.6%

Quarter to September 2026, against a year earlier

111.54 0.85 −0.76%
Market cap
$5.3B
P/E
88.7×
Fwd P/E
146×
Dividend yield
—
F-score
n/a
Altman Z
6.04
Beneish M
−2.03
Dividend safety
n/a

BillionToOne, Inc. (BLLN) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, BillionToOne, Inc. (BLLN) trades at a P/B ratio of 9.9×. Over the past ten years it has ranged from 0.0× (December 2025) to 13.0× (August 2026); the current reading is higher than 84% of that period. That is above the Diagnostics & Research industry median of 3.4× and above the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 2.7× —
FY2024 0.0× —
FY2023 0.0× —

Quarterly newest first

Period P/B ratio Change
Sep 2026 9.4× (9.63%)
Jun 2026 10.4× 44.63%
Mar 2026 7.2× 165.00%
Dec 2025 2.7× —
4 more quarters

Against its own ten years

Low 0.0× High 13.0×
Ten-year median 7.8×
Current reading's percentile 84

P/B ratio against peers

Company P/B ratio
VCYT Veracyte, Inc. compare 1.4×
GRAL GRAIL, Inc. compare 2.4×
NEO NeoGenomics, Inc. compare 2.7×
QGEN QIAGEN N.V. compare 3.1×
RDNT RadNet, Inc. compare 4.4×
SHC Sotera Health Company compare 6.2×
CDNA CareDx, Inc. compare 8.6×
BLLN BillionToOne, Inc. 9.9×
ADPT Adaptive Biotechnologies Corporation compare 23.5×
Diagnostics & Research industry median 3.4×
Healthcare sector median 2.3×
Market median 1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on BLLN